The effect of risedronate on hypogonadal osteoporotic HIV males treated with highly active anti-retroviral therapy: a pilot study

2014 ◽  
Author(s):  
Jessica Pepe ◽  
Andrea M Isidori ◽  
Mario Falciano ◽  
Giancarlo Iaiani ◽  
Alessandra Salotti ◽  
...  
Keyword(s):  
Pilot Study ◽  
Highly Active

Sequential neoadjuvant chemotherpy with nab-paclitaxel plus gemcitabine and FOLFIRINOX in locally advanced pancreatic cancer (LAPC): A PILOT study.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15193-e15193 ◽  
Author(s):  
Volker Kunzmann ◽  
Ingo Hartlapp ◽  
Michael Scheurlen ◽  
Hermann Einsele ◽  
Justus Mueller ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Pilot Study ◽  
Neoadjuvant Chemotherapy ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
Sensory Neuropathy ◽  
Disease Stage ◽  
Ductal Adenocarcinoma ◽  
Hematological Toxicity ◽  
Highly Active

e15193 Background: Nab-Paclitaxel (nab-P) + Gemcitabin (G) and FOLFIRINOX have both shown promising activity in metastatic pancreatic cancer (mPC). Our group has developed sequential usage of both regimens in order to exploit the stromal depletion effects of nab-P and increase global efficacy of chemotherapy in the neoadjuvant setting of LAPC. Methods: This pilot study evaluated patients with cytological/histological confirmed diagnosis of locally advanced pancreatic ductal adenocarcinoma without evidence of metastatic disease (stage III). nab-P+G was administered for 2 cycles (nab-P 125 mg/m2, G 1000 mg/ 2; on days 1, 8, 15; every 28 days) followed by 2 cycles of FOLFIRINOX (as reported by Conroy et al., NEJM 2011). Results: We report the preliminary analysis of 8 pts treated in our institution. Patients characteristics were M/F: 5/3; median age 63 (46-79); PS 0/1: 6/2. 3 pts (37%) had a biliary stent before starting treatment. All pts received the planned 4 cycles of neoadjuvant chemotherapy without dose reductions. There were no treatment-related deaths and none of pts stopped treatment due to toxicity. Grade 3-4 toxicities were neutropenia (50 %), nausea (12%), diarrhea (12%) and thrombopenia (25%). Grade 2-3 sensory neuropathy occured in 25% of pts. Prior nab-P+G did not result in increased hematological or non-hematological toxicity of FOLFIRINOX. Among the 8 patients evaluable so far, 5 partial responses (63%) and 3 stable disease (37%) have been observed, resulting in a disease control rate of 100%. After sequential chemotherapy 3 pts (37%) underwent radical surgical resection. Of note, all resected patients pts showed regression of the tumor (Evans Regression Score 2-4) with 1 patient fullfilling the criteria of a complete pathological remission (pCR). 4 pts received concomitant chemo-radiotherapy and 1 pt underwent an explorative laparotomy with evidence of occult (micronodular) peritoneal metastasis. Conclusions: Sequential neoadjuvant chemotherapy with nab-P+G and FOLFIRINOX seems to be highly active with manageable toxicity profile and may allow to achieve pCR in LAPC. These results are encouraging to test this approach in a prospective phase II trial.

scholarly journals African ethnicity can influence immunological responses to highly active antiretroviral therapy and immunological success at 48 months: a retrospective pilot study

2013 ◽  
Vol 17 (12) ◽  
pp. e1259-e1262 ◽  
Author(s):  
Christelle Guillaume ◽  
Yohan N’Guyen ◽  
Véronique Brodard ◽  
Firouze Bani-Sadr ◽  
Roland Jaussaud ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Pilot Study ◽  
Highly Active Antiretroviral Therapy ◽  
Immunological Responses ◽  
Highly Active

The Use of Cell Phone Reminder Calls for Assisting HIV-Infected Adolescents and Young Adults to Adhere to Highly Active Antiretroviral Therapy: A Pilot Study

2006 ◽  
Vol 20 (6) ◽  
pp. 438-444 ◽  
Author(s):  
Joseph A. Puccio ◽  
Marvin Belzer ◽  
Johanna Olson ◽  
Miguel Martinez ◽  
Cathy Salata ◽  
...  
Keyword(s):  
Young Adults ◽  
Antiretroviral Therapy ◽  
Pilot Study ◽  
Highly Active Antiretroviral Therapy ◽  
Cell Phone ◽  
Adolescents And Young Adults ◽  
Highly Active

scholarly journals A multiomics approach to identify host-microbe alterations associated with infection severity in diabetic foot infections: a pilot study

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Michael Radzieta ◽  
Fatemah Sadeghpour-Heravi ◽  
Timothy J. Peters ◽  
Honghua Hu ◽  
Karen Vickery ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Pilot Study ◽  
Diabetic Foot ◽  
Microbial Composition ◽  
Highly Active ◽  
Diabetic Foot Infections ◽  
Significant Enrichment ◽  
Differential Gene ◽  
Extremity Amputation ◽  
Host Genes

AbstractDiabetic foot infections (DFIs) are a major cause of hospitalization and can lead to lower extremity amputation. In this pilot study, we used a multiomics approach to explore the host–microbe complex within DFIs. We observed minimal differences in the overall microbial composition between PEDIS infection severities, however Staphylococcus aureus and Streptococcus genera were abundant and highly active in most mild to moderate DFIs. Further, we identified the significant enrichment of several virulence factors associated with infection pathogenicity belonging to both Staphylococcus aureus and Streptococcus. In severe DFIs, patients demonstrated a greater microbial diversity and differential gene expression demonstrated the enrichment of multispecies virulence genes suggestive of a complex polymicrobial infection. The host response in patients with severe DFIs was also significantly different as compared to mild to moderate DFIs. This was attributed to the enrichment of host genes associated with inflammation, acute phase response, cell stress and broad immune-related responses, while those associated with wound healing and myogenesis were significantly depleted.

Pilot Study of a Combination of Highly Active Antiretroviral Therapy and Cytokines to Induce HIV-1 Remission

2001 ◽  
Vol 26 (1) ◽  
pp. 44-55 ◽  
Author(s):  
Alain Lafeuillade ◽  
Cécile Poggi ◽  
Stéphane Chadapaud ◽  
Gilles Hittinger ◽  
Martine Chouraqui ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Pilot Study ◽  
Highly Active Antiretroviral Therapy ◽  
Highly Active ◽  
Hiv 1

Pilot Study of a Combination of Highly Active Antiretroviral Therapy and Cytokines to Induce HIV-1 Remission

2001 ◽  
Vol 26 (1) ◽  
pp. 44-55 ◽  
Author(s):  
Alain Lafeuillade ◽  
Cécile Poggi ◽  
Stéphane Chadapaud ◽  
Gilles Hittinger ◽  
Martine Chouraqui ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Pilot Study ◽  
Highly Active Antiretroviral Therapy ◽  
Highly Active ◽  
Hiv 1

A Pilot Study of the Safety and Inununogenicity of An HIV-1 Clade a Gag/Multiepitope DNA Vaccine, pTHr.HIVA, in HIV-1 Seropositive Subjects Receiving Highly Active Antiretroviral Therapy

2003 ◽  
Vol 104 (s49) ◽  
pp. 54P-54P
Author(s):  
Lucy Dorrell ◽  
Hongbing Yang ◽  
Christopher Conlon ◽  
Annie Suttill ◽  
Mary Lancaster ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Pilot Study ◽  
Dna Vaccine ◽  
Highly Active Antiretroviral Therapy ◽  
Highly Active ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document